NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

BLTE

Belite Bio Inc ADR

Jul 14 • 04:00PM ET

63.58

Dollar change +0.36
Percentage change 0.57	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX BIIB GILD MRNA BMY AMGN PFE LLY ABBV

| Held by: SPEM EWX ONEQ BBC GXC APIE

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.36	Insider Own	-	Shs Outstand	32.54M	Perf Week	8.44%
Market Cap	2.07B	Forward P/E	-	EPS next Y	-1.61	Insider Trans	-	Shs Float	-	Perf Month	4.06%
Enterprise Value	1.91B	PEG	-	EPS next Q	-0.41	Inst Own	0.72%	Short Float	-	Perf Quarter	8.65%
Income	-42.55M	P/S	-	EPS this Y	-45.76%	Inst Trans	-36.24%	Short Ratio	4.04	Perf Half Y	13.66%
Sales	0.00M	P/B	13.09	EPS next Y	6.28%	ROA	-32.07%	Short Interest	0.17M	Perf YTD	0.76%
Book/sh	4.86	P/C	13.14	EPS next 5Y	59.80%	ROE	-33.43%	52W High	86.53 -26.52%	Perf Year	27.67%
Cash/sh	4.84	P/FCF	-	EPS past 3/5Y	-43.42% -777.09%	ROIC	-26.92%	52W Low	43.70 45.49%	Perf 3Y	53.09%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.90% 3.90%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-15.56%	Oper. Margin	-	ATR (14)	2.59	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	24.31	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	57.02	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	24.31	EPS Q/Q	-67.80%	SMA20	5.70%	Beta	-1.51	Target Price	93.75
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	2.82%	Rel Volume	3.16	Prev Close	63.22
Employees	25	LT Debt/Eq	0.00	Earnings	May 14 BMO	SMA200	2.58%	Avg Volume	41.25K	Price	63.58
IPO	Apr 29, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	-27.84% -	Trades		Volume	125,270	Change	0.57%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-14-23	Initiated	Maxim Group	Buy	$60
Jul-28-23	Initiated	Cantor Fitzgerald	Overweight	$43
Jul-26-23	Initiated	SVB Securities	Outperform	$25
Aug-01-22	Initiated	H.C. Wainwright	Buy	$58
Jul-01-22	Initiated	The Benchmark Company	Buy	$57

Jul-03-25 12:01PM	Enrolment concludes in Belite Bios trial of Tinlarebant for geographic atrophy (Clinical Trials Arena)
Jul-02-25 03:00AM	Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy (GlobeNewswire)
May-21-25 03:00AM	Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease (GlobeNewswire)
May-16-25 08:35AM	Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire)
May-15-25 07:01PM	Belite Bio Inc (BLTE) Q1 2025 Earnings Call Highlights: Strong Financial Position Amid Rising ... (GuruFocus.com) +8.88%
09:00PM	Loading…
May-13-25 09:00PM	Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
03:00AM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 15, 2025 (GlobeNewswire)
May-12-25 08:00PM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 15, 2025 (GlobeNewswire)
08:35AM	Belite Bio, Inc to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference May 15th (GlobeNewswire)
08:00AM	Belite Bio to Participate in Four Upcoming Investor Conferences (GlobeNewswire)
May-08-25 10:44AM	UPDATE - International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 15, 2025 (GlobeNewswire)
08:35AM	International companies to host live webcasts at Deutsche Banks Depositary Receipts Virtual Investor Conference on May 15, 2025 (GlobeNewswire)
May-07-25 08:00AM	Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2025 Financial Results (GlobeNewswire)
Apr-29-25 08:00AM	Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting (GlobeNewswire)
Mar-17-25 06:00AM	Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
06:00AM	Loading…
06:00AM	Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website (GlobeNewswire)
Mar-11-25 03:00AM	Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-04-25 08:00AM	Belite Bio to Participate in the Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-27-25 02:00AM	Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects (GlobeNewswire)
Feb-05-25 10:35PM	Belite Bio Announces Registered Direct Offering of $15 Million (GlobeNewswire)
Nov-27-24 03:00AM	Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007 (GlobeNewswire) +5.34%
Nov-12-24 01:00AM	Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-05-24 08:00AM	Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-03-24 04:00PM	Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds (GlobeNewswire)
Oct-14-24 08:00AM	Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting (GlobeNewswire)
Oct-08-24 08:00AM	Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit (GlobeNewswire) +5.93%
Sep-26-24 08:51AM	Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire)
Sep-19-24 02:30AM	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 (GlobeNewswire)
Sep-17-24 11:22AM	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 (GlobeNewswire)
Sep-10-24 08:00AM	Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease (GlobeNewswire)
08:00AM	Loading…
Sep-03-24 08:00AM	Belite Bio to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Sep-01-24 08:00AM	Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer (GlobeNewswire)
Aug-09-24 09:52PM	BLTE Stock Earnings: Belite Bio Misses EPS for Q2 2024 (InvestorPlace)
04:30PM	Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Aug-08-24 08:00AM	Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire) +5.33%
Aug-05-24 07:10PM	Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-08-24 08:00AM	Belite Bio to Present at the JonesHealthcare Seaside Summit (GlobeNewswire) +6.81%
Jun-12-24 02:55AM	Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan (GlobeNewswire)
May-14-24 08:00AM	Belite Bio to Participate in the Benchmark's 4th Annual Healthcare House Call Investor Conference (GlobeNewswire)
07:53AM	BLTE Stock Earnings: Belite Bio Misses EPS for Q1 2024 (InvestorPlace)
05:17AM	Belite Bio's Q1 Loss Narrows (MT Newswires)
May-13-24 09:50PM	Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
08:00AM	Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire)
May-08-24 08:00AM	Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results (GlobeNewswire)
May-06-24 08:15AM	Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant (GlobeNewswire)
08:00AM	Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting (GlobeNewswire)
May-01-24 04:15PM	Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting (GlobeNewswire)
Apr-26-24 06:21AM	Belite Bio Unveils Plan to Offer 651,380 American Depository Shares (MT Newswires)
Apr-25-24 07:15PM	Belite Bio Announces $25 Million Registered Direct Offering (GlobeNewswire)
Apr-10-24 09:55AM	Does Belite Bio (BLTE) Have the Potential to Rally 41.14% as Wall Street Analysts Expect? (Zacks)
Mar-22-24 08:00AM	Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan (GlobeNewswire)
Mar-11-24 10:28PM	Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website (GlobeNewswire) -12.47%
09:27PM	Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-06-24 08:00AM	Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-04-24 08:00AM	Belite Bio to Participate in the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-07-24 08:00AM	Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Nov-30-23 08:00AM	Belite Bio to Participate in the Benchmark Company's Upcoming Discovery One-on-One Investor Conference (GlobeNewswire) +10.10%
Nov-20-23 08:00AM	Belite Bio to Participate in the BTIG Ophthalmology Day (GlobeNewswire)
Nov-13-23 08:15PM	Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results (GlobeNewswire)
Nov-10-23 08:35AM	Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire)
Nov-07-23 08:00AM	Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-06-23 04:00PM	Belite Bio, Inc. to present at the Deutsche Bank ADR Virtual Investor Conference on 8 November 2023 (GlobeNewswire)
08:00AM	Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting (GlobeNewswire)
Nov-01-23 08:35AM	International companies to host live webcasts at Deutsche Bank's Depositary Receipts (GlobeNewswire) +5.04%
Oct-31-23 08:35PM	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023 (GlobeNewswire)
Oct-27-23 08:00AM	Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting (GlobeNewswire)
Aug-21-23 11:12AM	Belite Bio (BLTE) Stock Surges 72% in a Month: Here's Why (Zacks)
Aug-08-23 10:17PM	Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results (GlobeNewswire)
Aug-04-23 08:00AM	Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results (GlobeNewswire) +10.63%
Jul-31-23 07:57AM	Is Belite Bio, Inc (NASDAQ:BLTE) Worth US$24.1 Based On Its Intrinsic Value? (Simply Wall St.)
Jul-27-23 05:00PM	Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA (GlobeNewswire) +10.37% +17.27%
Jul-24-23 06:04AM	Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease (GlobeNewswire)
Jun-30-23 04:09PM	Why Shares of Belite Bio Soared This Week (Motley Fool)
May-31-23 12:22PM	Why Shares of Belite Bio Are Slumping Wednesday (Motley Fool) -31.09%
May-30-23 08:49PM	Belite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and Warrants (GlobeNewswire)
04:01PM	Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and Warrants (GlobeNewswire)
May-10-23 07:58PM	Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results (GlobeNewswire)
03:33PM	Belite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial Results (GlobeNewswire)
May-04-23 11:09AM	Belite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 Data (GlobeNewswire)
Apr-25-23 04:30PM	Belite Bio Presented 18-Month Interim Data from a 24-Month Phase 2 Study of Tinlarebant in Adolescent Stargardt Disease at the 2023 ARVO Meeting (GlobeNewswire)
Apr-11-23 09:00AM	Belite Bio to Host Key Opinion Leader Webinar on RBP4 Antagonist Tinlarebant in Late-Stage Development for Stargardt Disease 1 (GlobeNewswire)
Apr-08-23 09:02AM	We're Interested To See How Belite Bio (NASDAQ:BLTE) Uses Its Cash Hoard To Grow (Simply Wall St.)
Mar-31-23 07:03PM	Belite Bio Reports Full-Year 2022 Operational Highlights and Financial Results (GlobeNewswire)
12:57PM	Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial Results (GlobeNewswire)
Jan-09-23 08:45AM	3 Breakout Growth Stocks to Buy for the Long Haul (Motley Fool)
Dec-08-22 05:14AM	2 Stocks Up 165% and 209% in 2022 That Could Keep Soaring in 2023 (Motley Fool)
Nov-18-22 08:00AM	Belite Bio Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008) (GlobeNewswire)
Oct-20-22 08:00AM	Belite Bio to Host Key Opinion Leader Webinar on October 27, 2022 to discuss LBS-008 Interim Data (GlobeNewswire)
Oct-03-22 04:07PM	Why Top-Rated Biotechs Apellis, Belite Are Among The Worst Performers Today (Investor's Business Daily) -13.26%
Oct-01-22 07:03PM	Belite Bio Presented 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease at AAO Annual Meeting 2022 (GlobeNewswire)
Sep-23-22 08:00AM	Belite Bio Announces Late-Breaking Presentation at the American Academy of Ophthalmology 2022 Annual Meeting (GlobeNewswire) -5.08%
Sep-16-22 08:00AM	Belite Bio Receives Approval of LBS-008 Phase 3 Clinical Trial in China (GlobeNewswire) +9.17%
Aug-22-22 08:00AM	Belite Bio Initiates Pivotal Phase 3 Clinical Trial of LBS-008 in Stargardt Disease in the U.S. (GlobeNewswire) +18.92%
Aug-10-22 09:51PM	Belite Bio Reports First Half 2022 Operational Highlights and Financial Results (GlobeNewswire) +5.30%
Aug-01-22 04:10PM	Belite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial Results (GlobeNewswire)
02:36PM	'Novel Approach For Retinal Disease Needs' Stock Belite Bio Has 70% Potential Upside According To This Analyst (Benzinga)
Jul-30-22 10:47AM	We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely (Simply Wall St.)
Jul-19-22 04:05PM	Belite Bio Submits Investigational New Drug (IND) Application to FDA for Approval to Proceed with LBS-008 Phase 3 Clinical Trial for the Treatment of Stargardt Disease (GlobeNewswire) +5.25% -22.17%
May-12-22 04:30PM	Belite Bio Announces Partial Exercise of Over-Allotment Option in Initial Public Offering (GlobeNewswire)
May-05-22 08:00AM	Belite Bio Presented Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022 (GlobeNewswire) +15.16%

Belite Bio, Inc. engages in the research and development of drugs. It focuses on the treatment of eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. It also caters to metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. The company was founded by Yu-Hsin Lin on March 27, 2018 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
Yu-Hsin Lin	CEO, Chairman	May 21 '25	Proposed Sale	64.81	120,400	7,803,124	May 21 04:30 PM
Nathan Mata	Affiliate	Mar 19 '25	Proposed Sale	67.80	30,166	2,045,126	Mar 19 04:28 PM
Yu-Hsin Lin	CEO, Chairman	Jan 02 '25	Proposed Sale	63.10	162,000	10,222,200	Jan 02 04:44 PM
Hao-Yuan Chuang	Officer, Director	Jan 02 '25	Proposed Sale	63.10	160,000	10,096,000	Jan 02 04:39 PM
Wei-Cheng Liaw	affiliate	Nov 20 '24	Proposed Sale	82.53	5,999	495,097	Nov 20 06:25 PM
Nathan Mata	Affiliate	Nov 19 '24	Proposed Sale	82.34	30,000	2,470,200	Nov 19 06:17 PM
Yu-Hsin Lin	CEO, Chairman	Oct 03 '24	Proposed Sale	48.00	40,000	1,920,000	Oct 03 08:50 PM
Hao-Yuan Chuang	Officer, Director	Oct 03 '24	Proposed Sale	48.00	40,000	1,920,000	Oct 03 08:48 PM
Wei-Cheng Liaw	affiliate	Sep 20 '24	Proposed Sale	48.14	6,500	312,910	Sep 20 12:40 PM
Wan Shan Chen	affiliate	Sep 04 '24	Proposed Sale	48.10	6,650	319,865	Sep 04 12:29 PM
Nathan Mata	affiliate	Aug 16 '24	Proposed Sale	500.00	30,000	15,000,000	Aug 16 06:24 PM
Hao-Yuan Chuang	Officer, Director	Aug 14 '24	Proposed Sale	49.32	100,000	4,932,000	Aug 14 04:32 PM
Yu-Hsin Lin	CEO, Chairman	Aug 14 '24	Proposed Sale	49.32	100,000	4,932,000	Aug 14 04:30 PM
Chiu, Ching Chen	affiliate	Aug 14 '24	Proposed Sale	49.84	34,568	1,722,869	Aug 14 02:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BLTE

Belite Bio Inc ADR

Upgrade your FINVIZ experience